Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
1.690
+0.060 (3.68%)
Oct 14, 2025, 3:37 PM EDT - Market open
Werewolf Therapeutics Revenue
In the year 2024, Werewolf Therapeutics had annual revenue of $1.89M, down -90.55%.
Revenue (ttm)
$1.89M
Revenue Growth
-90.55%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
46
Market Cap
77.28M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.89M | -18.06M | -90.55% |
Dec 31, 2023 | 19.94M | 3.54M | 21.60% |
Dec 31, 2022 | 16.40M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
HOWL News
- 6 days ago - Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - GlobeNewsWire
- 11 days ago - Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 6 weeks ago - Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit - GlobeNewsWire
- 4 months ago - Werewolf Therapeutics to Participate in the BIO International Convention - GlobeNewsWire
- 4 months ago - Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 - GlobeNewsWire